Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 June 2021Website:
http://www.lyell.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 20 Jun 2024 22:26:30 GMTDividend
Analysts recommendations
Institutional Ownership
LYEL Latest News
Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of patients with relapsed/refractory metastatic or advanced melanoma, NSCLC, and colorectal cancer are expected in 2024. Lyell Immunopharma is advancing a 2nd generation CAR-T known as LYL119 and an IND submission for it is expected in 1st half of 2024. It is also advancing a second-generation TIL.
Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline includes LYL797, a CART cell targeting TNBC and NSCLC, and LYL845, a TIL targeting melanoma, NSCLC, and CRC. Lyell's proprietary technologies have shown improved proliferation, functionality, and antitumor efficacy in preclinical trials. However, the company's valuation has decreased, and there are concerns about the ROR1 targeting space.
It was another wild ride in the stock market today. Whether you were trading penny stocks or Tesla, the thing weighing on everyone's conscience was the outcome of the June Fed meeting.
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14 at 2:00pm PT.
Lyell Immunopharma (LYEL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.28 per share a year ago.
What type of business is Lyell Immunopharma?
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
What sector is Lyell Immunopharma in?
Lyell Immunopharma is in the Healthcare sector
What industry is Lyell Immunopharma in?
Lyell Immunopharma is in the Biotechnology industry
What country is Lyell Immunopharma from?
Lyell Immunopharma is headquartered in United States
When did Lyell Immunopharma go public?
Lyell Immunopharma initial public offering (IPO) was on 17 June 2021
What is Lyell Immunopharma website?
https://www.lyell.com
Is Lyell Immunopharma in the S&P 500?
No, Lyell Immunopharma is not included in the S&P 500 index
Is Lyell Immunopharma in the NASDAQ 100?
No, Lyell Immunopharma is not included in the NASDAQ 100 index
Is Lyell Immunopharma in the Dow Jones?
No, Lyell Immunopharma is not included in the Dow Jones index
When does Lyell Immunopharma report earnings?
The next expected earnings date for Lyell Immunopharma is 08 August 2024